Tag: Chemrar

ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate built in Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide.

The mission of the company is to develop and commercialise existing drugs on the basis of novel “post-genomic” technologies used for treatment of cancer, infectious, cardiovascular and central nervous system (CNS) diseases as well metabolic disorders.

ChemRar performs a full cycle of pre-clinical and clinical research of new molecules including screening and identification of the essential biological targets for new molecules, synthesis and research of new molecules as well as full cycle of production.

Since 2007 CHT “ChemRar” in liaison with the Federal Science and Innovation Agency (ROSNAUKA) started a joint financing on a parity basis of a three-year project for development series of high efficient clinical candidates for treatment of infectious diseases. The project was set up on the basis of the Yaroslavl State Pedagogic University and called “Intellectual Dialog” Ltd.

RDIF and ChemRar Group launch JV for Production of Antiviral Drug Favipiravir

The Supervisory Board of the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, has approved the creation of a Joint Venture (JV) with ChemRar Group aimed at the production of Favi...

ChemRar Announced Successful Completion of Phase II Clinical Trials of AB5080

molecules pic
ChemRar, a Russian pharmaceutical research company, has announced the successful completion of the second phase of clinical trials of a new domestic drug effective against type A and B flu strains, in...

ChemRar Presented Positive Results of AVN-101 Phase II Clinical Trials

The Avineiro project of the ChemRar R&D Institute completed a multicenter, randomized, double-blind, placebo-controlled pilot study of the efficacy, safety and dosing regimen of the innovative dru...

ChemRar has started the production of HIV drug

ChemRar, a Russian company based in the business incubator of the city of Khimki, began to produce a drug for HIV‐infected patients. This is not a cure for AIDS, but a so-called “preventive drug”.

The study of the Aurixim new indications has started

Conjugate announced that it began to study new indications for Aurixim use in anti-β-cell therapy of autoimmune pathology

An innovative Russian drug registered for treatment of HIV infection

viriom chemrar
ELPIDA®, a new generation non-nucleoside reverse transcriptase inhibitor and the first original Russian drug in the 21st century for the treatment of HIV infection, was registered in Russia

Trials conducted by ChemRar confirm the safety of a new anti-flu medicine

ChemRar Group announced successful completion of clinical trials to assess safety and tolerability of AV5080, a fundamentally new oral drug candidate formulation with a broad spectrum of anti-flu acti...

More than 20 medicines have been launched to the Russian market

pharma skolkovo
The results of project implementation were discussed at the meeting of the general committee of the Presidential Council of the Russian Federation for Economic Modernization and Innovative Development...